Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 15/20 | 1.00 |
| ▸ | CTSL | P07711 | 3/20 | 1.00 |
| ▸ | CTSB | P07858 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | CTSG | P08311 | 1/20 | 1.00 |
| ▸ | CAPN9 | O14815 | 3/20 | 0.72 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.72 |
| ▸ | CTSH | P09668 | 1/20 | 0.49 |
| ▸ | CTSS | P25774 | 1/20 | 0.49 |
| ▸ | CTSK | P43235 | 1/20 | 0.49 |
| ▸ | CTSC | P53634 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aloxistatin SCHEMBL12620387 | 1.00 | CAPN1 (1.00) | CAPN1CTSLCTSBLMNACTSG | |
| Aloxistatin SCHEMBL21981208 | 1.00 | CAPN1 (1.00) | CAPN1CTSLCTSBLMNACTSG | |
| Aloxistatin SCHEMBL21981210 | 1.00 | CAPN1 (1.00) | CAPN1CTSLCTSBLMNACTSG | |
| Aloxistatin SCHEMBL254426 | 1.00 | CAPN1 (1.00) | CAPN1CTSLCTSBLMNACTSG | |
| Aloxistatin SCHEMBL18498407 | 1.00 | CAPN1 (1.00) | CAPN1CTSLCTSBLMNACTSG | |
| SCHEMBL22273610 | 0.93 | CAPN1 (0.87) | CAPN1CTSLCTSBLMNACTSG | |
| Aloxistatin SCHEMBL9314220 | 0.93 | CAPN1 (0.86) | CAPN1CTSLCTSBLMNACTSG | |
| SCHEMBL12653864 | 0.91 | CAPN1 (0.83) | CAPN1CTSLCTSBLMNACTSG | |
| SCHEMBL1804811 | 0.91 | CAPN1 (0.83) | CAPN1CTSLCTSBLMNACTSG | |
| SCHEMBL12653616 | 0.91 | CAPN1 (0.83) | CAPN1CTSLCTSBLMNACTSG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 833 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250387462-A1 | LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS AND VACCINE FOR THE PREVENTION OF TUBERCULOSIS OR OTHER MYCOBACTERIAL INFECTIONS | AKAGERA MEDICINES, INC. (US) | 2025-12-25 | — | — | US | claimed |
| EP-4662491-A2 | EXPEDITED NEOANTIGEN VACCINES | Iogenetics, LLC. (US) | 2025-12-17 | — | — | EP | claimed |
| EP-4662329-A1 | CLEAVED NEOEPITOPES | Iogenetics, LLC. (US) | 2025-12-17 | — | — | EP | claimed |
| EP-4648769-A2 | NECROSIS INHIBITOR | Linkgevity Limited (GB) | 2025-11-19 | — | — | EP | claimed |
| CN-120131940-A | Bile duct cancer treatment medicine composition and application thereof | 安徽省立医院(中国科学技术大学附属第一医院) | 2025-06-13 | — | — | CN | claimed |
| US-20250152531-A1 | INHIBITORS OF AUTOPHAGY AND DCAR-1 AS NOVEL ANTHELMINTIC AGENTS | FLORIDA ATLANTIC UNIVERSITY BOARD OF TRUSTEES | 2025-05-15 | — | — | US | claimed |
| WO-2025096764-A1 | THERAPEUTIC TARGETING OF TUMOR ESCAPE BY CAR-MEDIATED TROGOCYTOSIS | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2025-05-08 | — | — | WO | claimed |
| US-20250064804-A1 | COMBINATION THERAPY FOR TREATING ABNORMAL CELL GROWTH | RGCM SA LLC, AS PURCHASER AGENT | 2025-02-27 | — | — | US | claimed |
| US-12233036-B2 | Inhibitors of autophagy and DCAR-1 as novel anthelmintic agents | FLORIDA ATLANTIC UNIVERSITY BOARD OF TRUSTEES (US) | 2025-02-25 | — | — | US | claimed |
| US-20250043285-A1 | Mammalian ATG8 Proteins and ATG9A Direct Sealing of Autophagosomal Membranes | UNM RAINFOREST INNOVATIONS (US) | 2025-02-06 | — | — | US | claimed |
| WO-2011017600-A2 | COMPOSITIONS AND METHODS FOR TREATING BETA-AMYLOID RELATED DISEASES | AMERICAN LIFE SCIENCE PHARMACEUTICALS, INC. (ALSP INC.) (US) | 2011-02-10 | — | — | WO | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-20060205671-A1 | Compositions and methods for use of a protease inhibitor and adenosine for preventing organ ischemia and reperfusion injury | EMORY UNIVERSITY | 2006-09-14 | — | — | US | claimed |
| EP-1638579-A2 | COMPOSITIONS AND METHODS FOR USE OF A PROTEASE INHIBITOR AND ADENOSINE FOR PREVENTING ORGAN ISCHEMIA AND REPERFUSION INJURY | EMORY UNIVERSITY (US) | 2006-03-29 | — | — | EP | claimed |
| WO-2005003150-A2 | COMPOSITIONS AND METHODS FOR USE OF A PROTEASE INHIBITOR AND ADENOSINE FOR PREVENTING ORGAN ISCHEMIA AND REPERFUSION INJURY | EMORY UNIVERSITY (US) | 2005-01-13 | — | — | WO | claimed |
| CN-1548157-A | SARS resisting medicine action target and its preventing and treating medicine | 北京摩力克科技有限公司 | 2004-11-24 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250387462-A1 | LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS AND VACCINE FOR THE PREVENTION OF TUBERCULOSIS OR OTHER MYCOBACTERIAL INFECTIONS | CD4, MICA, LNPK | CAPN1 2446/4885CTSL 405/4885CTSB 1170/4885 |
| US-20250043285-A1 | Mammalian ATG8 Proteins and ATG9A Direct Sealing of Autophagosomal Membranes | ATG7, BECN1, ATG4A | CAPN1 2402/4885CTSL 2586/4885CTSB 597/4885 |
| US-20250064804-A1 | COMBINATION THERAPY FOR TREATING ABNORMAL CELL GROWTH | NRAS, BRAF, BECN1 | CAPN1 2596/4885CTSL 2805/4885CTSB 717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.